Merial announced today the release of a new equine vaccine–RECOMBITEK Equine West Nile Virus (WNV) vaccine. The recent USDA approval of RECOMBITEK Equine West Nile Virus vaccine offers veterinarians a first-of-its-kind product backed by cutting-edge science to offer fast-acting and long-lasting protection from the often deadly WNV. (Click here for an earlier article on the vaccine.)

“The RECOMBITEK West Nile Virus vaccine uses recombinant DNA technology to stimulate a fast, multifaceted and long-lasting immune response proven by natural mosquito challenge of West Nile virus,” says Mike Murray, DVM, MS, Merial Equine Technical Director for Strategic Development. “The fast-acting immune response was demonstrated in a controlled trial that showed horses were protected from viremia caused by West Nile virus infection when challenged as early as two weeks after completion of the two-vaccination series